Answers are grounded in this paper and cite their sources.
The immunologic response rate is considerable compared with previous GV1001 trials without concomitant chemotherapy, although low toxicity is retained. The results warrant further studies of GV1001/temozolomide treatment and support the general concept of combining cancer vaccination with chemotherapy.
No takes yet. Share an insight, caveat, or question.
Kyte et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: